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Abstract
Background: Non-unions are severe complications in orthopaedic trauma care and occur in 10% of all
fractures. The golden standard for the treatment of ununited fractures includes open reduction and
internal fixation (ORIF) as well as augmentation with autologous-bone-grafting. However, there is
morbidity associated with the bone-graft donor site and some patients offer limited quantity or quality of
autologous-bone graft material. Since allogene bone-grafts are introduced on the market, this comparative
study aims to evaluate healing characteristics of ununited bones treated with ORIF combined with either
iliac-crest-autologous-bone-grafting (ICABG) or demineralized-bone-matrix (DBM).
Methods and results: From 2000 to 2006 out of sixty-two consecutive patients with non-unions
presenting at our Level I Trauma Center, twenty patients had ununited diaphyseal fractures of long bones
and were treated by ORIF combined either by ICABG- (n = 10) or DBM-augmentation (n = 10). At the
time of index-operation, patients of the DBM-group had a higher level of comorbidity (ASA-value: p =
0.014). Mean duration of follow-up was 56.6 months (ICABG-group) and 41.2 months (DBM-group). All
patients were clinically and radiographically assessed and adverse effects related to bone grafting were
documented. The results showed that two non-unions augmented with ICABG failed osseous healing
(20%) whereas all non-unions grafted by DBM showed successful consolidation during the first year after
the index operation (p = 0.146). No early complications were documented in both groups but two patients
of the ICABG-group suffered long-term problems at the donor site (20%) (p = 0.146). Pain intensity were
comparable in both groups (p = 0.326). However, patients treated with DBM were more satisfied with the
surgical procedure (p = 0.031).
Conclusion: With the use of DBM, the costs for augmentation of the non-union-site are more expensive
compared to ICABG (calculated difference: 160 €/case). Nevertheless, this study demonstrated that the
application of DBM compared to ICABG led to an advanced outcome in the treatment of non-unions and
simultaneously to a decreased quantity of adverse effects. Therefore we conclude that DBM should be
offered as an alternative to ICABG, in particular to patients with elevated comorbidity and those with
limited availability or reduced quality of autologous-bone graft material.
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Introduction
The development of non-unions depends on several fac-
tors, such as energy-level of trauma, type of fracture, soft
tissue involvement, type of applied treatment, and various
endogenous factors [1-3]. According to literature, non-
union will occur in approximately 10% of fractures after
conservative or operative treatment [4]. The use of iliac
crest autologous bone graft (ICABG) is widely considered
as gold standard for a number of reasons, including oste-
ogenic, osteoconductive, and osteoinductive properties
and the lack of disease transmission or of immunogenic-
ity [5-7]. However, the use of autograft may be at risk of
major drawbacks, such as limited availability and variable
quality of the graft, hematoma, infection, increased oper-
ative time and bleeding, chronic donor site pain, and
additional cost [8-15]. Subsequently, research has focused
on the development of novel bone graft substitutes for the
last decades [16,17].
In 1965, Urist at al. first described an osteoinductive sub-
stance while preparing soluble extracts from demineral-
ized bone [18]. Since this pioneering work, a large body of
data obtained by preclinical animal studies has supported
the utility of demineralized bone matrix (DBM) in human
clinical settings. Nevertheless, there still is a lack of clinical
studies: A recent MEDLINE search using the term "dem-
ineralized bone matrix" restricted to "clinical study" and
"English language" demonstrated, that only four refer-
ences were found that were dealing with DBM-treatment
in cases of a non-union of long bones [5,19-22]. There-
fore, De Long et al. concluded that evidence for or against
the use of DBM is still at a low level (Level-IV or V studies
with consistent findings) [17].
In 2000, DBM Grafton® (Osteotech Inc., Eatontown, NJ,
USA) was introduced in our Department of Trauma Sur-
gery as an alternative to iliac crest autologous bone graft
(ICABG), particularly for morbid patients or those with
decreased quantity or quality of autologous bone graft.
Therefore, the aim of the present study was to report our
experience in augmenting non-unions either with DBM or
ICABG.
Methods
Patients
All patients presenting to our Level I trauma centre during
a seven year period (01/2000 - 12/2006) with ununited
fractures of upper and lower extremities' long bones were
retrospectively selected for the study. Non-union was
defined as the lack of bone healing by at least six months
after fracture. For analysis, we compared those patients
who had had ORIF and augmentation with ICABG
("autologous-group") and those with the use of deminer-
alized bone matrix (DBM Grafton®; Osteotech, Eaton-
town, New Jersey) ("allograft-group"). Further inclusion
criteria were: (1) patient over 18 years; (2) atrophic and
diaphyseal non-union; (3) no segmental defect; (4)
closed fracture or open I° according to the Gustilo-classi-
fication at initial presentation [23] and no clinical, radio-
graphic, or laboratory evidence of infection; (5) not more
than one previous operation at the non-union site; and
(6) a minimum of 12 months of follow-up after index
operation. We excluded patients fulfilling any of the fol-
lowing criteria: fractures secondary to a malignant tumor,
immunosuppressive therapy, severe systemic disease or
history of reflex sympathetic dystrophy and patients
receiving other augmentation types than either ICABG or
DBM.
During the observational period sixty-two consecutive
patients with ununited long bone fractures were identi-
fied. Of these patients, two subjects were treated conserv-
atively, twenty-two victims had intraarticular fractures,
fourteen met at least one exclusion criterion and four
patients were operated by using an autograft and allograft
composite and therefore had to be excluded, because they
could not be assigned for one of the two study groups.
Thus 10 patients were identified in the autologous- and
10 patients in the allograft-group.
Surgical Procedure
All surgical procedures were performed under the supervi-
sion of experienced orthopaedic trauma surgeons and fol-
lowed a specific operation-protocol: All patients obtained
a single shot antibiotic (1.5 g cefuroxime i.v.) straight pre-
operatively and underwent general anaesthesia. After
exposure of the non-union site, several specimens for
microbiological cultures were obtained. In case of prior
fracture-instrumentation, implants were removed. There-
after, non-union site was radically debrided of intervening
scar tissue and sclerotic bone fragments with preservation
of muscle and soft-tissue attachments to avoid devascular-
ization. In addition, the medullary canal was opened both
proximally and distally to complete the freshening of the
bone ends. The non-union site was then reduced ade-
quately by gently impacting the distal into the proximal
fragment to obtain osseous contact and thereafter pre-
pared for bone-grafting. The selection of the bone-graft-
type, either ICABG or DBM (DBM Grafton® Putty 2.5 cc;
Osteotech, Eatontown, New Jersey), was based on the
experience of the surgeon in charge. The graft was placed
into the medullary canal and around the nonunion site.
Finally, the bone ends were instrumented to achieve sta-
ble fixation of the ununited fracture. Intraoperative anter-
oposterior and lateral radiographs were used to confirm
adequate placement of hardware and bone alignment.
Follow-up
After hospitalization for the index-operation, all patients
were clinically and radiographically investigated at ourJournal of Trauma Management & Outcomes 2009, 3:11 http://www.traumamanagement.org/content/3/1/11
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orthopaedic trauma outpatient department until the end
of the non-union-related treatment. For the purpose of
this study, follow-up was performed at least twelve
months after the index-operation. Data assessment was
performed by one investigator, who was not involved in
the non-union treatment of the patients (A.W.). Blinding
of the investigator was obviously not possible since all
patients treated by ICABG were easily identifiable by the
scar at the iliac crest donor site.
All patients completed the standardized baseline and fol-
low-up questionnaire to obtain general information
about the baseline data as well as the course of fracture
treatment and non-union healing. Thereafter, the stand-
ardized telephone-interview was performed by the inves-
tigator to clarify the data. Sex, age, ASA value (American
Society of Anaesthesiologists classification), body-mass-
index (BMI), smoking status, time from trauma to index-
operation and time from index-operation to follow-up
were documented. Additionally, all postoperative compli-
cations related to the index-operation were documented.
Furthermore, intensity of persistent pain at the prior unu-
nited fracture site as well as the donor site in ICABG-
patients was recorded by the use of a numeric rating scale
(NRS) ranging from 0 (no pain) to 10 (maximum of
pain). Clinical healing was defined as full weight bearing
or complete function. Osseous healing was defined as a
radiologically complete bridging callus formation with
crossing trabeculae on anteroposterior and lateral radio-
graphs obtained during the study period. All x-rays were
investigated by study-independent radiologists. Further-
more, the level of patient's dissatisfaction concerning the
non-union surgical procedure was documented with the
use of a numeric rating scale (NRS) (range 0 to 5) by the
following specifications: (0) satisfied, (1) minimal dissat-
isfied, (2) marginal dissatisfied, (3) partial dissatisfied,
(4) mostly dissatisfied, and (5) extremely dissatisfied.
In case of insufficient quality of outcome data obtained by
the follow-up questionnaire and the telephone-interview,
patients were evaluated by the investigator clinically and
x-rays of the surgical site were taken if necessary. For anal-
ysis, patient's personal data were anonymized.
Statistical Analysis
For the comparison of both study groups (autologous-
group and allograft-group) the Mann-Whitney U test was
used to evaluate the differences with regard to the demo-
graphic and follow-up data. The Spearman rank correla-
tion coefficient was used to evaluate the association
between various factors (patient's age, sex, the American
Society of Anaesthesiologists classification, BMI, prior
fracture treatment, as well as smoking behaviour) and
outcome after index-operation. Level of significance was
set at p ≤ 0.05.
Results
As shown in table 1, no differences were documented
between the autologous- and allograft-group concerning
demographic data, BMI, smoking behaviour, location of
non-union, prior instrumentation at non-union site, and
mean time from ununited fracture to index-surgery. ASA
values were significantly higher in the allograft-group,
indicating that these patients had more comorbidities at
the time of surgery (p = 0.014). In both groups, compara-
ble types of implants were used for fixation of united frac-
ture during index-surgery (p = 0.255).
Follow-up
As shown in table 2, the mean follow-up time was 56.6
months (range 18-87 months) in the autologous and 41.2
months (range 12-69 months) in the allograft-group (p =
0.240). The mean time for clinical healing was compara-
ble in both groups (p = 0.168) as well as for radiological
consolidation (p = 0.327). Nevertheless, there was a lack
of bone bridging in two patients treated by ICABG (autol-
ogous healing-rate: 80%) whereas all ununited fractures
treated by DBM showed completed bone healing during
the study period (allograft-healing-rate: 100%) (p =
0.146). Both patients of the autograft-group who failed to
heal after the index-operation had a persistent non-union
located at the forearm: One patient was a 34 year old male
non-smoker who had to be re-operated 19 months after
the index-operation because of pain, reduction of arm-
function and implant failure at the ulna (see figure 1). The
second ICABG-treated patient with impaired consolida-
tion was a 57 year old male non-smoker. His x-rays twelve
months after the index operation showed a stiff non-
union with a good alignment and no radiological signs for
implant loosening. Since he had no pain, no decreased
arm-function during daily life activities and no reduction
in his professional tasks as family doctor, he refused revi-
sion of the persistent non-union (see figure 2).
Donor site complications
One obvious difference between the two groups was the
additional surgery for iliac crest bone harvesting in the
autologous-group. These patients showed a donor-site-
related morbidity rate of 20% since one subject suffered
permanent pain at the iliac crest (VAS 3) and another vic-
tim complained about disabling keloid-formation at the
donor-site-scar, which was associated with moderate pain
(VAS 2) (p = 0.146). None of the patients suffered harvest-
ing-related swelling, redness, drainage, infection or neuro-
logical deficits.
Intensity of pain and level of treatment-dissatisfaction
At follow-up, patients of the both groups stated to have
approximately equal intensity of index-operation-related
pain (at rest: p = 0.326; with physical activity: p = 0.936)
(see table 2). Additionally, four patients of the autolo-Journal of Trauma Management & Outcomes 2009, 3:11 http://www.traumamanagement.org/content/3/1/11
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gous-group (40%) compared to all patients of the allo-
graft-group (100%) were satisfied or only minimally
dissatisfied with the non-union treatment. Thus, patients
of the allograft-group were significantly less dissatisfied
with the treatment compared to those of the autologous-
group (p = 0.031) (see table 2).
Discussion
The ideal bone graft substitute should provide three key
elements: (1) osteogenetic cells to facilitate bone regener-
ation; (2) osteoinductive factors to induce bone forma-
tion; and (3) an osteoconductive matrix to directly
stimulate bone deposition. Osteoconductive materials
have no capability to form bone or induce its formation
per se. They merely provide an interconnected biocompat-
ible scaffold, which local osseous tissue can utilize to
regenerate living bone. Osteoinductive materials facilitate
new bone formation by allowing cells in the local envi-
ronment to undergo phenotypic conversion to osteopro-
genitor cell types capable of formation of bone.
"Osteogenic" is a graft material that has the inherent
capacity to form bone, which implies that it has cells such
as osteoblasts or osteocytes, capable of producing bone
[2,4-7,16,17,24].
In this context, the best available alternative to autologous
bone grafting is the use of an allograft. However, currently
available allograft DBM formulations may differ consider-
ably with regard to their bone inductive activity, mainly
dependent on biological properties of the graft and the
methods of allograft preparation [24]. DBM Grafton®
(Osteotech Inc., Eatontown, NJ, USA), which was used in
this study as bone substitute in the allograft-group, is a
type of processed allograft bone in combination with glyc-
erin. As shown in animal studies, DBM Grafton® has oste-
oconductive and osteoinductive potential: histologically,
new bone formation could be shown after DBM-applica-
tion [25,26].
Only few clinical studies are published to demonstrate
DBM-efficacy as bone substitute and even less reports doc-
umented the outcome of DBM used in the treatment of
long bone non-unions [5,17]. In 2003, Wilkens et al. pub-
lished data using an injectable type of DBM called "Allo-
Matrix Injectable Putty": 30 of 35 patients with non-union
in multiple bone types went on to union in an average of
3.5 months [21]. The same author showed that the percu-
taneous use of a mixture of autologous bone marrow and
allograft DBM (AlloMatrix) led in 61 of 69 patients with
Table 1: Baseline data in patients with ununited long bone fractures treated by ORIF and augmentation with either autograft (n = 10) 
or allograft (n = 10).
autograft group allograft
group
p-value
Mann-Whitney-Test
Sex [n] 0.383
male 6 4
female 4 6
Age [years] 0.289
mean 50.6 57.9
range 27-81 31-85
Body-mass-index [m/kg2] 0.450
mean 25.0 24.5
range 19.2-28.4 18.8-39.0
Smoking-Status [package-yrs] 0.466
mean 1.2 5.0
range 0-12 0-30
Location of non-union [n] 0.420
upper arm 2 4
forearm 5 2
femur 0 3
lower leg 3 1
Fracture to index surgery [months] 0.183
mean 8.7 14.6
range 6-16 6-54
Prior instrumentation [n] 0.654
none 2 5
plate 7 2
intramedullary device 1 3
ASA Score 0.014
mean 1.4 2.1
range 1-2 1-3Journal of Trauma Management & Outcomes 2009, 3:11 http://www.traumamanagement.org/content/3/1/11
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stiff non-unions of long bones to union in an average
period of 8.1 months [22]. Unfortunately, both studies
were performed without a control group leading to a
decreased Level of Evidence [5]. In 2005, Ziran et al.
reported data of a retrospective comparative study using
cancellous bone chips combined either with DBM
Grafton® (n = 25) or with DBM Orthoblast (n = 13) for the
treatment of non-unions or impending non-unions in
heavy smokers: Healing on the first graft attempt was
observed in 52% of the DBM Grafton® and 85% of the
DBM Orthoblast group [20]. Since this study used DBM in
combination with another graft-type, the question kept
unanswered, in what extent the observed results were
influenced by DBM. In 2006, Hierholzer et al. published
a retrospective consecutive cohort study of ununited dia-
physeal fractures of the humerus. Cases were treated with
open reduction and internal fixation using a reconstruc-
tion plate and either iliac crest bone graft (n = 45) or DBM
Grafton® (n = 43). In the iliac crest bone group, clinical
and radiological union was achieved in 100% in an aver-
age of 4.5 months compared to 97% in the Grafton® group
in 4.2 months [19]. One limitation of that study might be
that the results are applicable only for the diaphyseal
humerus non-unions, since DBM was used only in this
specific long bone.
The aim of the present study was to evaluate the effect of
DBM compared to ICABG in the treatment of non-unions
of extraarticular long-bones in the upper and lower
extremities. Since patients' baseline data as well as the
observed radiological and pain intensity outcome during
follow-up was comparable in both groups our study could
demonstrate, that DBM has the same biological efficacy in
promoting bone healing of non-unions compared to
ICABG. Nevertheless, 20% of the autologous-group suf-
fered considerable long term donor site complications at
the iliac crest region. Additionally, patients treated by
ICABG claimed elevated dissatisfaction concerning the
non-union surgical procedure compared to those of the
allograft-group during follow-up.
Since it is well known, that the biological potential of
bone healing is progressively impaired by the rising
number of previous interventions at the bone site [27],
only patients with a maximum of one previous operation
at the non-union were selected for this study. Hence, our
analysis did not show a correlation of non-union-healing
associated either with previous non-operative fracture
treatment or previous surgery (p = 0.329). Additionally, it
is well documented that smokers are significantly more at
risk to develop complicated fracture healing [1,10,27]. In
the present study, there were only three smokers among
the evaluated non-union patients: one smoker with 12
package years in the in the autologous-group and two
smokers with a mean value of 25 package years in the allo-
graft-group, respectively. Consequently, the low rate of
Table 2: Follow-up data in patients with ununited long bone fractures treated by ORIF and augmentation with either autograft (n = 10) 
or allograft (n = 10).
autograft group allograft
group
p-value
Mann-Whitney-Test
Follow-up time [months] 0.240
mean 56.6 41.2
range 18-87 12-69
Incidence of Bone Consolidation [n] 8 10 0.146
% (80%) (100%)
Healing time: clinical [months] 0.168
mean 8.3 4.1
range 2-24 2-8
Healing time: radiological [months] 0.327
mean 10.9 11.9
range 2-40 2-21
Pain intensity: at rest [NRS] 0.326
mean 2.0 1.1
range 0-6 0-5
Pain intensity: with physical activity [NRS] 0.936
mean 2.3 2.2
range 0-7 0-6
Level of treatment-dissatisfaction** [NRS] 0.031
mean 2.9 1.4
range 0-5 0-2
* Pain intensity at follow-up were documented by the Numeric Rating Scale with a range from 0 (no pain) to 10 (maximum pain).
**Level of dissatisfaction concerning non-union surgical procedure at follow-up were documented by the Numeric Rating Scale ranging from of 0 
(satisfied) to 5 (extremely dissatisfied).Journal of Trauma Management & Outcomes 2009, 3:11 http://www.traumamanagement.org/content/3/1/11
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smokers led to the low mean value of package years in
each group, probably resulting in a lack of correlation
between non-union-healing and smoking behavior (p =
0.176). In addition, the analysis did not show an associa-
tion between the non-union-consolidation and patient's
age (p = 0.312), sex (p = 0.242), BMI (p = 0.116), and ASA
value (p = 0.576).
There are some possible disadvantages associated with the
use of allografts. The first detriment is the additional cost
for surgery compared to autologous bone grafting. How-
ever, Lohmann et al. evaluated recently the economic
impact of ICABG in trauma surgery [28]. Mainly because
of the extended operation time, harvesting was calculated
to cost 213 €. In our study, all patients of the allograft-
group were treated with the use of 2.5 cc Grafton® Putty,
which was announced in Osteotech's pricelist to cost 373
€. Thus, considering the economical aspect of both non-
union procedures, DBM costs 160 € more compared to
ICABG. The second handicap of allografts might be the
potential immunogenicity compared to autologous graft-
ing which was shown not only in animal models [29] but
also probably in clinical applications [30-32]. Fortu-
nately, we did not observe allograft-related immunologi-
cal adverse reactions in our study but this potential
problem should be considered using DBM.
Beside the disadvantages shown above, there are several
benefits associated with the use of allografts. The doubt-
less advantages of DBM are first the unlimited availability,
second the reduced operative time and bleeding, and
third the avoidance of donor site complications which
were documented in 20% of our study-patients treated by
ICABG [8-15]. An additional advantage of DBM might be
the beneficial effect in patients with more comorbidity: As
documented in our trial, ASA values were significantly ele-
vated in the allograft-group (p = 0.014). Despite this less
advantageous cohort of patients treated with DBM, the
incidence of non-union healing was comparable in both
study groups. Based on these data we conclude that DBM
is particularly advisable in morbid patients because of
proved effectiveness in promoting non-union healing.
The limitations of the present study include first the small
number of patients in each treatment group which is
probably the result of a decreased rate of non-unions
X-ray of the right forearm 19 months after ORIF of a 34 year  old man showing a persistent non-union of the ulna Figure 1
X-ray of the right forearm 19 months after ORIF of a 
34 year old man showing a persistent non-union of 
the ulna.
X-ray of the right forearm 12 months after ORIF of a 57 year  old man showing a persistent non-union of the radius Figure 2
X-ray of the right forearm 12 months after ORIF of a 
57 year old man showing a persistent non-union of 
the radius.Journal of Trauma Management & Outcomes 2009, 3:11 http://www.traumamanagement.org/content/3/1/11
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because of advanced therapy-options in acute fracture
treatment [3]. Second, the investigator could not be
blinded with regard to the donor-site scar at the iliac crest,
thus follow-up data were not blindly assessed. Neverthe-
less, the research fellow was not the treating physician and
therefore we do not think that lack of blinding influenced
the findings of the study. Furthermore, since pain inten-
sity and treatment-satisfaction (NRS) was self-assessed by
patients and x-rays were evaluated by a study-independent
radiologist a potential assessor-related bias could be min-
imized. Third, the non-prospective design and conse-
quently a lack of randomization is a weakness of the
study.
Conclusion
In conclusion, we successfully incorporated augmentation
with demineralized bone matrix allograft into a standard
concept for the treatment of atrophic ununited extraartic-
ular fractures of long bones in upper and lower extremi-
ties. Demineralized bone matrix proved to be equally
effective as autologous bone graft in augmenting ORIF,
since the healing incidence and time for consolidation of
ununited fractures as well as pain intensity at follow-up
was comparable in both groups. Nevertheless, autologous
cancellous bone graft should still be considered as the
gold standard in the treatment of non-unions, since at the
present time first there is no better evidence available that
supports the superiority of allografts and second allograft-
ing is more expensive. However, our study showed that
patients treated by allograft-augmentation had no com-
plications, reduced treatment-dissatisfaction, and a lack of
donor site complications at the iliac crest region. There-
fore we found our results adequately sound to conclude
that the use of DBM should be offered to suitable patients
in the preoperative consultation as a valuable alternative
for autologous grafting. Moreover, we recommend non-
union treatment with ORIF and augmentation with allo-
grafts first in morbid patients to reduce operative time and
perioperative donor site complications, and second in
patients with known osteopenia/osteoporosis and there-
fore limited availability of cancellous bone for autologous
grafting. The low number of study patients, lack of rand-
omization and the non-prospective study design weaken
the power of this study. Hence, there is a need for further
in-depth multicenter-investigations to verify not only our
results but also to get further validated information about
additional factors in order to optimize successful consoli-
dation in long bone non-unions.
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